Alkermes plc
ALKSNext catalyst
ALKS 2680
Narcolepsy Type 2
Get an email about ALKS's next catalysts
Track Alkermes (ALKS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 5 more upcoming events in our data (Phase 3 readout, earnings, Phase 2 readout).See the timeline
6 upcoming, 0 past
ALKS 2680 Phase 2 Est. Readout (Vibrance-3)
Estimated primary completion for ALKS 2680 trial (NCT06843590) in Idiopathic Hypersomnia. Topline data typically follows completion by weeks to months.
SourceALKS 2680 Dose 3 Phase 3 Est. Readout
Estimated primary completion for ALKS 2680 Dose 3 trial (NCT07502443) in Narcolepsy Type 2. Topline data typically follows completion by weeks to months.
SourceALKS 2680 Dose 1 Phase 3 Est. Readout (Brilliance NT1)
Estimated primary completion for ALKS 2680 Dose 1 trial (NCT07455383) in Narcolepsy Type 1. Topline data typically follows completion by weeks to months.
SourceALKS 2680 Dose 1 Phase 3 Est. Readout
Estimated primary completion for ALKS 2680 Dose 1 trial (NCT07540897) in Narcolepsy Type 1. Topline data typically follows completion by weeks to months.
SourceALKS Earnings Report
EPS Est: $-0.08 | FQ end Sep/2026 | Call: bmo
ALKS 7290 Phase 2 Est. Readout
Estimated primary completion for ALKS 7290 trial (NCT07755410) in Attention Deficit Disorder With Hyperactivity (ADHD). Topline data typically follows completion by weeks to months.
SourceHow ALKS's past catalysts played out
Market Overview
Stock performance and key metrics
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.
WebsiteXR-NTX
Alcohol Use Disorder
ALKS 9072
Schizophrenia
Human Insulin Inhalation Powder
Diabetes Mellitus, Type 1
High Dose ALKS 5461
Major Depressive Disorder
NTX/BUP
Opioid Use Disorder
Naltrexone
Amphetamine-Related Disorders
Extended-Release Naltrexone
Opiate Dependence
Medisorb naltrexone
Opiate Dependence
Injectable insulin
Diabetes Mellitus, Type 1
Paliperidone Palmitate
Schizophrenia
ALKS 3831
Schizophrenia
ALKS 9072, Low
Schizophrenia
ALK3831
Schizophrenia
ALKS 9072, High
Schizophrenia
ALKS 9072, High Dose
Schizophrenia
OLZ/SAM
Schizophrenia
intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
Diabetes Mellitus, Type 2
VIVITROL
Alcohol Dependence
ALKS 9072, Low Dose
Schizophrenia
ALKS
Narcolepsy Type 1
Low Dose ALKS 5461
Major Depressive Disorder
ALKS 2680 Dose 2
Narcolepsy Type 1
VIVITROL®
Opiate Dependence
ALKS 2680 Dose 1
Narcolepsy Type 1
ALKS 2680 Dose 3
Narcolepsy Type 2
ALKS 8700
Multiple Sclerosis
ALKS 5461
Major Depressive Disorder
buprenorphine/naloxone
Opiate Dependence
N1539
Hysterectomy
ALKS 37
Opioid-induced Constipation
ALKS 2680
Narcolepsy Type 2
Samidorphan (Low Dose)
Schizophrenia
Motrin
Dental Pain
TrIP-2D
Chronic Obstructive Pulmonary Disease (COPD)
RDC-1036 (ALKS 37)
Opioid-induced Constipation
RDC-0313 (ALKS 33)
Binge Eating Disorder
ALKS33 (RDC-0313)
Alcohol Dependence
ALKS 7290
Attention Deficit Disorder With Hyperactivity (ADHD)
Samidorphan + olanzapine (ALKS 3831)
Schizophrenia
VIVITROL (Naltrexone extended-release injectable suspension)
Cocaine Dependence
very low dose naltrexone
Opiate Dependence
Hydromorphone
Opiate Dependence
ALKS 7290 Dose
Major Depressive Disorder (MDD)
Samidorphan (High Dose)
Schizophrenia
Naloxone Challenge and Oral Naltrexone Tolerability Testing
Opiate Dependence
Samidorphan (Medium Dose)
Schizophrenia
Active Cannabis
Cannabis
TrIP-2SS
Chronic Obstructive Pulmonary Disease (COPD)
TrIP-2SS + Foradil
Chronic Obstructive Pulmonary Disease (COPD)
extended release naltrexone
Opiate Dependence
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
XR-NTX | Phase 3 | Alcohol Use Disorder | - | - |
ALKS 9072 | Phase 3 | Schizophrenia | - | - |
Human Insulin Inhalation Powder | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
High Dose ALKS 5461 | Phase 3 | Major Depressive Disorder | - | - |
NTX/BUP | Phase 3 | Opioid Use Disorder | - | - |
Naltrexone | Phase 3 | Amphetamine-Related Disorders | - | - |
Extended-Release Naltrexone | Phase 3 | Opiate Dependence | - | - |
Medisorb naltrexone | Phase 3 | Opiate Dependence | - | - |
Injectable insulin | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Paliperidone Palmitate | Phase 3 | Schizophrenia | - | - |
ALKS 3831 | Phase 3 | Schizophrenia | - | - |
ALKS 9072, Low | Phase 3 | Schizophrenia | - | - |
ALK3831 | Phase 3 | Schizophrenia | - | - |
ALKS 9072, High | Phase 3 | Schizophrenia | - | - |
ALKS 9072, High Dose | Phase 3 | Schizophrenia | - | - |
OLZ/SAM | Phase 3 | Schizophrenia | - | - |
intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
VIVITROL | Phase 3 | Alcohol Dependence | - | - |
ALKS 9072, Low Dose | Phase 3 | Schizophrenia | - | - |
ALKS | Phase 3 | Narcolepsy Type 1 | - | - |
Low Dose ALKS 5461 | Phase 3 | Major Depressive Disorder | - | - |
ALKS 2680 Dose 2 | Phase 3 | Narcolepsy Type 1 | - | - |
VIVITROL® | Phase 3 | Opiate Dependence | - | - |
ALKS 2680 Dose 1 | Phase 3 | Narcolepsy Type 1 | - | - |
ALKS 2680 Dose 3 | Phase 3 | Narcolepsy Type 2 | - | - |
ALKS 8700 | Phase 3 | Multiple Sclerosis | - | - |
ALKS 5461 | Phase 3 | Major Depressive Disorder | - | - |
buprenorphine/naloxone | Phase 2 | Opiate Dependence | - | - |
N1539 | Phase 2 | Hysterectomy | - | - |
ALKS 37 | Phase 2 | Opioid-induced Constipation | - | - |
ALKS 2680 | Phase 2 | Narcolepsy Type 2 | - | - |
Samidorphan (Low Dose) | Phase 2 | Schizophrenia | - | - |
Motrin | Phase 2 | Dental Pain | - | - |
TrIP-2D | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
RDC-1036 (ALKS 37) | Phase 2 | Opioid-induced Constipation | - | - |
RDC-0313 (ALKS 33) | Phase 2 | Binge Eating Disorder | - | - |
ALKS33 (RDC-0313) | Phase 2 | Alcohol Dependence | - | - |
ALKS 7290 | Phase 2 | Attention Deficit Disorder With Hyperactivity (ADHD) | - | - |
Samidorphan + olanzapine (ALKS 3831) | Phase 2 | Schizophrenia | - | - |
VIVITROL (Naltrexone extended-release injectable suspension) | Phase 2 | Cocaine Dependence | - | - |
very low dose naltrexone | Phase 2 | Opiate Dependence | - | - |
Hydromorphone | Phase 2 | Opiate Dependence | - | - |
ALKS 7290 Dose | Phase 2 | Major Depressive Disorder (MDD) | - | - |
Samidorphan (High Dose) | Phase 2 | Schizophrenia | - | - |
Naloxone Challenge and Oral Naltrexone Tolerability Testing | Phase 2 | Opiate Dependence | - | - |
Samidorphan (Medium Dose) | Phase 2 | Schizophrenia | - | - |
Active Cannabis | Phase 2 | Cannabis | - | - |
TrIP-2SS | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
TrIP-2SS + Foradil | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
extended release naltrexone | Phase 2 | Opiate Dependence | - | - |
Frequently asked questions
What is in Alkermes plc's drug pipeline?→
CatalystAlert tracks 50 drug candidates in Alkermes plc's (ALKS) pipeline across Phase 3, Phase 2. Its lead program is ALKS 2680 Dose 1 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alkermes plc's next FDA catalyst?→
Alkermes plc's (ALKS) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALKS biotech catalysts?→
Add ALKS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alkermes plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.